List of Tyvaso drug patents
Tyvaso is owned by United Therap.
Tyvaso contains Treprostinil.
Tyvaso has a total of 6 drug patents out of which 0 drug patents have expired.
Tyvaso was authorised for market use on 30 July, 2009.
Tyvaso is available in solution;inhalation dosage forms.
Tyvaso can be used as method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device.
The generics of Tyvaso are possible to be released after 15 December, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
| US10376525 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
| US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(5 years from now) | |
| US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Mar 31, 2024 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION;INHALATION
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic